No Data
No Data
J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls. -- Barrons.com
Traders Digest Key Earnings as US Equity Futures Tread Water Pre-Bell
Express News | J&J: Treatment With Nipocalimab Plus Soc Met Study's Primary Endpoint of Reduction in Total Serum Igg (-69%)
Express News | Nipocalimab Demonstrates Sustained Disease Control in Adolescents Living With Generalized Myasthenia Gravis in Phase 2/3 Study
Express News | J&J Shares Reverse Course Premarket; Last Down 1%
Johnson & Johnson Stock Rises on Q3 Sales Beat and Guidance Raise
loading...
No Data
No Data
Silverbat OP : The worst is slowly away